GlassScriptPhysician profile
Nicolas Jaeggi
NPI 1396478673
$547.23
in general payments reported to CMS, 2019-2025
15 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $47.63 · 2023: $73.79 · 2024: $128 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $108.38 | 2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $80.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $69.06 | 2022-2025 | Farxiga, Airsupra |
| Madrigal Pharmaceuticals | $54.33 | 2025 | Rezdiffra |
| Organon LLC | $30.49 | 2025 | Nexplanon |
| Abbvie INC. | $28.51 | 2022 | |
| Corium, LLC | $25.81 | 2025 | Azstarys |
| Amgen INC. | $21.72 | 2025 | Otezla, Repatha |
| Novo Nordisk INC | $21.52 | 2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $20.84 | 2024 | Mounjaro |
| Insulet Corporation | $19.01 | 2024 | Omnipod |
| Novartis Pharmaceuticals Corporation | $18.74 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.14 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $16.17 | 2024 | Uzedy |
| Janssen Pharmaceuticals, INC | $13.83 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Jaeggi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.